- The European Commission (EC) has approved Merck & Co Inc's MRK soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat).
- Verquvo (2.5 mg, 5 mg, and 10 mg) is indicated to treat symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy.
- Merck has the commercial rights to Verquvo in the U.S., and Bayer AG BAYRY has the exclusive commercial rights in the rest of the world.
- In January, the FDA approved Verquvo.
- Price Action: MRK shares are up 0.42% at $76.49 during the premarket session on the last check Wednesday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
